About BioMark

Providing universal access to cancer diagnostics and early stage detection by leveraging the power of new technology.

Who We Are

Oncology Focused

BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites.

We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory, clinical and scientific standards.

Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.

biomark diagnostics oncology focused ribbon
about-3.png
biomark diagnostics empowering people little girl and doctor
about-4.png

We Why Are

Empowering People

To empower people, medical institutions and nations to gain universal access to effective cancer diagnostic tools.

In essence, we accelerate and facilitate effective cancer management solutions to improve patient outcome.

Adherence To Rigorous Standards

Because of the critical role that biomarkers play at all stages of disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation, and assessment of clinical utility, prior to incorporation into routine clinical care. This is an important dimension of BioMark’s daily operational activity.

about-3.png

BioMark Diagnostics Response to Treatment

BioMark Diagnosis Cancer Survivorship Program

BioMark Diagnostics Screening Tool

BioMark's Team

Collectively, our core leadership team consists of research doctors with many decades of diagnostic development, engineering and biochemistry researchers, as well as experienced business professionals. The entire team has been selected to drive discovery, reduce regulatory and technical risks, accelerate clinical adoption and liaise with biopharma.

Executive Team

Rashid Ahmed Bux, MBA – Founder, Chief Executive Officer

Dr. Jeff Haince, Ph.D – Chief Scientific Officer and GM

Dr. Bram Ramjiawan, Ph.D – Clinical Trial and Regulatory Expertise

Brian Cheng, MSc– Chief Technical Officer

Gina Huang, MBA – CFO and Project Director

Research, Scientific, Clinical

Dr. Daniel Sitar – Principal Scientific Advisor / Professor Emeritus, University of Manitoba

Dr. David Wishart – Professor, Depts. of Computer Science and Biological Sciences, University of Alberta

Dr. Myron L. Weisfeldt – M.D., University Distinguished Service Professor, Professor of Medicine, The Johns Hopkins Hospital

Dr. Andrew Maksymiuk – Oncologist; Cancer Care Manitoba

Dr. Reuven Gordon – Professor, Canadian Research Chair in Nanoplasmonics, University of Victoria

Dr. Paramjit Tappia – Scientific and Clinical Researcher, St. Boniface Research Centre

Dr. John Yoo – Clinical Oncologist; Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario

Dr. Donald Miller – Professor, Department of Pharmacology and Therapeutics University of Manitoba

Dr. David Chen – Professor, Dept. of Chemistry, University of British Columbia

Dr. Horacio Bach – PhD, Antibody Engineering UBC

Alfred Berkeley – Strategic and financial advisor

Research

USA Clinical Research

Glioblastoma Multiforme resection and correlating it to existing anatomical imaging tests for confirmation is the initial trial to be led by Dr. Graeme F. Woodworth, MD (Professor, Department of Neurosurgery; Director, Brain Tumor Treatment and Research Center) who will serve as University of Maryland Baltimore (UMB’s) principal investigator in connection with such study(ies). The co- PI will be Dr. Chetan Bettegowda Director, Meningioma Center and Associate Professor of Neurosurgery at Johns Hopkins.

Validation studies on BioMark’s lung cancer panel for utilization in early lung cancer screening initiatives and measuring response to treatment will be led Dr. Christian D. Rolfo, MD, PhD, MBA (Professor, Department of Medicine; Director, Early Phase Clinical Trials – Department of Medicine; Director, Thoracic Medical Oncology – Department of Medicine) will serve as UMB’s principal investigator in connection with such study(ies).

biomark diagnostics clinical research woman examining slide
about-3.png

Kudos and Accolades

Executive Team & Advisors

Cross Pollinated, Balanced and Committed team since 2007.

Cancer Diagnostics

BioMark Pushing the Limit of Early Detection.

Awards, Grants, Recognitions

Sparks Grant, TMIC University of Alberta - Dr. David Wishart

Strategic Collaborations

Biopharmaceutical Research Inc. & University of Manitoba

Auditor

PricewaterhouseCoopers LLP

Legal Counsel

Miller Thomas LLP.

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.